Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
3 passages
Daunorubicin is an anthracycline antibiotic mainly used to treat various types of cancers, especially leukemias. It can be used to treat both acute and chronic leukemias. This activity will summarize the mechanism of action, adverse event profile, and other key factors (e.g., indications, contraindications, pharmacodynamics, pharmacokinetics, monitoring, relevant interaction) pertinent to daunorubicin therapy well as important prescribing and management consideration by the healthcare team. Objectives: Identify the mechanism of action and administration of daunorubicin. Describe the potential adverse effects of daunorubicin. Outline the appropriate monitoring necessary for patients receiving daunorubicin. Review interprofessional team strategies for improving care coordination communication to advance daunorubicin therapy and improve outcomes. Access free multiple choice questions on this topic.
Daunorubicin causes cardiotoxicity by forming complexes with topoisomerase IIb enzyme in cardiomyocytes. This activity is the same as when the drug forms complexes with topoisomerase IIa in tumor cells and can result in mitochondrial damage with subsequent myocardial cell death. Dexrazoxane is a cardio-protectant agent. Research has shown it to decrease the incidence and severity of cardiotoxicity when given from the first dose of anthracyclines without reducing the effectiveness of the chemotherapeutic agent. It acts by inhibiting the isomer of topoisomerase and decrease the free radical damage by chelating free iron.[7][9] It is administered intravenously in a ratio of 10 to 1 of dexrazoxane: daunorubicin. Cardiac monitoring is still a recommendation despite concurrent therapy, and if a patient develops a decline in the left ventricular function or develops symptomatic heart failure, treatment should discontinue immediately.
Due to the serious toxic effects of daunorubicin therapy, strong interprofessional communication and care coordination are recommended among oncologists, family clinicians (MDs, DOs, NPs, PAs), nurses, and pharmacists. Administration of the drug should only be by a team trained in leukemia chemotherapy and centers with training on monitoring drug tolerance, toxic monitoring, and surveillance. There should also be effective resources available to treat any adverse effects related to daunorubicin therapy especially acute fatal infections or severe hemorrhage related to bone marrow suppression and decompensations due to acute congestive heart; in that case, cardiology referral is immediately necessary. Dexarozoxane is recommended to prevent the cardiotoxic effects of daunorubicin and has shown effective results in large randomized clinical trials.[9]